Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart attack drug shows promise for Non-Diabetics

NCT ID NCT06903754

Disease control Sponsor: Mohammed VI University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study tested whether SGLT2 inhibitors (dapagliflozin or empagliflozin), taken daily, can reduce heart failure hospitalizations, repeat heart attacks, and death in 450 non-diabetic patients who had a heart attack treated with stenting. Participants received the drug on top of standard care. The goal is to see if these medications, already used in diabetes, can also protect the heart in people without diabetes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SGLT2 inhibitors (dapagliflozin or empagliflozin)
What this could lead to
If successful, this could show that SGLT2 inhibitors help prevent heart failure and reduce hospital readmissions in non-diabetic patients after a heart attack.
What could go wrong
The trial is completed but results are not yet widely confirmed. Benefits seen in diabetic patients may not fully apply to non-diabetics, and side effects like dehydration or kidney issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

450 people

The number who actually took part.

Started

Oct 2021

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient with Acute coronary syndrome

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria : * Participant must approved the informed consent. * Confirmed MI, either STEMI or NSTEMI, according to the fourth universal definition of MI (Thygesen et al 2019). * Evidence of impaired regional or global LV systolic function at any timepoint during current MI-related hospitalisation with Ejection Fraction\<50%(established with echocardiogram, radionuclide ventriculogram, contrast angiography or cardiac MRI) or Symptoms of Acute heart failure without cardiogenic Shock. * Hemodynamically stable (no episodes of symptomatic hypotension, or arrhythmia with haemodynamic compromise in the last 24 hours). Exclusion Criteria: * Known type 1 diabetes mellitus (T1DM) or T2DM at the time for admission. * Chronic symptomatic HF with a prior HHF within the last year and known reduced ejection fraction (LVEF≤40 %), documented before the current MI hospitalization. * Patients with cardiogenic shock who received vasoactive drugs during index. * Hospitalization Severe (eGFR \<20 mL/min/1.73 m2 by local laboratory), unstable or rapidly progressing renal disease at the time of randomization * Severe hepatic impairment (Child-Pugh class C) at the time of inclusion into the trial. * Active malignancy requiring treatment at the time of screening. * Any non-CV condition, eg malignancy, with a life expectancy of less than one years based on the investigator´s clinical judgement. * Currently on treatment, or with an indication for treatment, with a sodium glucose co-transporter 2 inhibitor (SGLT2-inhibitor)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndromes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome heart failure myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute coronary syndromes Heart failure

Contacts and locations

Locations

  • Mohammed VI university hospital oujda

    OUDA, Morocco

More trials for these conditions

Other studies related to the condition(s) this trial covers.